Moraxella Bovis Bacterin (Solidtech)

Verify with FDA CVM →

13 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
13
Total Reports
3
Deaths Reported
2310.0%
Death Rate

Active Ingredients

Moraxella Bovis Bacterin (Solidtech)

Administration Routes

SubcutaneousUnknown

Species Affected

Cattle 13

Most Affected Breeds

Cattle (other) 6
Aberdeen Angus 2
Mixed (Cattle) 2
Hereford cattle 1
Holstein-Friesian also known as Holstein 1
Red Angus 1

Most Reported Reactions

Lack of efficacy (bacteria) - NOS 7
Lack of efficacy - NOS 4
Death 2
Keratoconjunctivitis 2
Cloudy eye (for Miosis, Mydriasis, Anisocoria, Nystagmus - see 'Neurological') 2
Impaired vision 2
CULTURE/TITER DATA ABNORMAL 1
Abnormal necropsy finding 1
Pulmonary disorder NOS 1
Incorrect route of drug administration 1
Abortion 1
Stillbirth 1

Outcome Breakdown

Outcome Unknown
11 (64.7%)
Died
3 (17.6%)
Recovered/Normal
2 (11.8%)
Ongoing
1 (5.9%)

Data Summary

Metric Value
Total adverse event reports 13
Reports involving death 3
Case-fatality rate (reported events) 2310.0%
Distinct species in reports 1
Distinct breeds in reports 6
Distinct reactions reported 15
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Moraxella Bovis Bacterin (Solidtech) Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 13 adverse event reports referencing Moraxella Bovis Bacterin (Solidtech), including 3 reports in which the animal died — a 2310.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Moraxella Bovis Bacterin (Solidtech). Reported administration routes include Subcutaneous, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Moraxella Bovis Bacterin (Solidtech) reports are Cattle (13 reports), with Cattle accounting for the largest share. Within those species, Cattle (other) (6), Aberdeen Angus (2), Mixed (Cattle) (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Moraxella Bovis Bacterin (Solidtech) are Lack of efficacy (bacteria) - NOS (7), Lack of efficacy - NOS (4), Death (2), Keratoconjunctivitis (2). Of the 17 reports with a coded outcome, Outcome Unknown is the leading category at 64.7%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Moraxella Bovis Bacterin (Solidtech).

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial